Back to Search
Start Over
Biomarker-guided management reduces exacerbations in non-eosinophilic asthma in pregnancy: A secondary analysis of a randomized controlled trial.
- Source :
-
Respirology (Carlton, Vic.) [Respirology] 2020 Jul; Vol. 25 (7), pp. 719-725. Date of Electronic Publication: 2019 Oct 26. - Publication Year :
- 2020
-
Abstract
- Background and Objective: The aim of this secondary analysis of a randomized controlled trial (RCT) of asthma management in pregnancy was to determine the treatment decision differences between a symptom control algorithm and a fractional exhaled nitric oxide (FENO)-guided algorithm, and whether the approach was effective in non-eosinophilic asthma (NEA).<br />Methods: In this double-blind parallel group RCT, women with asthma were randomized prior to 22 weeks gestation to treatment adjustment according to a symptom control algorithm (control group), or a FENO-guided algorithm (inhaled corticosteroid (ICS) dose adjusted according to FENO with long-acting beta-agonist (LABA) added for uncontrolled symptoms). NEA was classified as baseline blood eosinophils <0.26 × 10 <superscript>9</superscript> /L and FENO ≤29 ppb. Exacerbations requiring medical intervention were recorded.<br />Results: Among 220 non-smokers (n = 109 control, n = 111 FENO), 1006 treatment decisions were made, with significant group differences after the first and second algorithm applications. 53% of women had NEA. Treatment was better targeted to phenotype in the FENO group: ICS use increased in eosinophilic asthma (EA, 48-86%), while ICS/LABA increased in NEA (11-30%). Fewer women in the FENO group had exacerbations during pregnancy in NEA only (18.9% FENO vs 44% control, P = 0.006).<br />Conclusion: The FENO algorithm was more effective in treating NEA, resulting in reduced exacerbations, compared to a symptom control algorithm. This was not the result of ICS overtreatment, since the benefits occurred at a lower median daily ICS dose. Two applications of the FENO-guided algorithm, one month apart, were sufficient to achieve beneficial effects in terms of asthma exacerbations, among pregnant women with asthma.<br /> (© 2019 Asian Pacific Society of Respirology.)
- Subjects :
- Administration, Inhalation
Adult
Algorithms
Asthma metabolism
Biomarkers
Breath Tests
Double-Blind Method
Eosinophils
Female
Humans
Phenotype
Pregnancy
Pregnancy Complications metabolism
Pulmonary Eosinophilia metabolism
Adrenal Cortex Hormones therapeutic use
Asthma drug therapy
Bronchodilator Agents therapeutic use
Nitric Oxide metabolism
Pregnancy Complications drug therapy
Pulmonary Eosinophilia drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1440-1843
- Volume :
- 25
- Issue :
- 7
- Database :
- MEDLINE
- Journal :
- Respirology (Carlton, Vic.)
- Publication Type :
- Academic Journal
- Accession number :
- 31656059
- Full Text :
- https://doi.org/10.1111/resp.13713